Assessing the Diagnostic Precision of Chosen Equational Scores in Detecting Steatosis through Elastography

Sajid Alhaidari, B Charfeddine, Talal Hadi

Abstract


Background: Several non-interventional imaging studies, scoring systems, and biochemical markers are widely used nowadays to urgently diagnose stage and manage cases of non-alcoholic fatty liver disease (NAFLD) to avoid potential complications. The current study aimed to compare the sensitivity, specificity, and positive predictive values (PPR) of some widely used NAFLD-induced steatosis scoring systems.

Methods: Fifty patients confirmed with fatty liver by ultrasonography were recruited in this study. All patients underwent steatosis staging using FibroScan. For all patients, aspartate transaminase (AST), alanine transaminase (ALT), platelet count, and body mass index were measured for the calculation of aspartate transaminase to platelet ratio index (APRI), hepatic steatosis index (HSI), and AST/ALT equations. Sensitivity, specificity, and PPR for the three scoring systems were calculated compared to FibroScan scoring results as the standard validating system where S0 and S1 scores were considered negative while S2 and S3 scores were considered positive for hepatic steatosis.

Results: Sensitivity results were 45, 87.8, and 45.9%; specificity results were 30, 22.2, and 69.2%; and PPR results were 72, 83.7, and 82.9% for APRI, HSI, and AST/ALT ratio scoring equation, respectively.

Conclusion: Among the three steatosis scoring systems studied in the present study, the HSI was the most sensitive scoring system, and the AST/ALT ratio was the most specific scoring system compared to the FibroScan as the standard steatosis scoring system.

Keywords: Equational Scores; Steatosis; Elastography; AST/ALT; APRI   


Full Text:

PDF

References


Mikolasevic I MS, Wensveen TT, Grgic I, Jakopcic I, Stimac D, et al. Nonalcoholic fatty liver disease – A multisystem disease? World Journal Gastroenterology, (2016); 22(43): 9488–9505.

Darvishi M AK, Toama MA, Hadrawi SK, Ramadan MF, Pirhadi M, et al. . A Review of the Effects of Omega-3 and Omega-6 on Alcoholic and Non-Alcoholic Fatty Liver. Advancements in Life Sciences, (2023); 10(4): 530–536.

Çiftçioğlu M KB, Ispiroğlu M, Gişi K. Frequency of fibrosis in patients with incidentally detected hepatosteatosis. Revista da Associação Médica Brasileira, (2023); 70(1): 1-5.

Waseem M SF, Khan R. Ultrasound Detected Non-Alcoholic Fatty Liver Disease Prevalence and its Risk Factors in Pakistani Population. Advancements in Life Sciences, (2022); 9(4): 607–611.

Joseph AE SS, al-Sam S, Cook MG, Maxwell JD.. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clinical radiology, (1991); 43(1): 26-31.

Dasarathy S DJ, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real-time ultrasound in the diagnosis of hepatic steatosis: a prospective study. Journal of hepatology, (2009); 51(6): 1061-1067.

Shiralkar K JS, Bluth EI, Marshall RH, Dornelles A, Gulotta PM. Improved method for calculating hepatic steatosis using the hepatorenal index. Journal of Ultrasound in Medicine, (2015); 34(6): 1051-1059.

Ballestri S LA, Romagnoli D, Carulli L, Losi L, Day CP, et al. . Ultrasonographic fatty liver indicator, a novel score that rules out NASH and is correlated with metabolic parameters in NAFLD. Liver International, (2012); 32(8): 1242-1252.

Chan WK NMN, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. Journal of gastroenterology and hepatology, (2014); 29(7): 1470-1476.

Sasso M BM, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary

study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in medicine & biology, (2010); 36(11): 1825-1835.

Liu K WV, Lau K, Liu SD, Tse YK, Yip TC, et al. . Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. Official journal of the American College of Gastroenterology| ACG, (2017); 112(12): 1812-1823.

De Matteis C CM, Graziano G, Battaglia S, Suppressa P, Piazzolla G, et al. . AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. Scientific Reports, (2021); 11(1): 1-14.

Sviklāne L OE, Dzērve Z, Kupčs K, Pīrāgs V, Sokolovska J. . Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. Journal of gastroenterology and hepatology, (2018); 33(1): 270-276.

Lee SS PS, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Noninvasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. Journal of hepatology, (2010); 52(4): 579-585.

Rodríguez-Antonio I L-SG, Reyes-Gómez VA, Contreras-Flores EH, Farías-García F, Espejel-Deloiza M, et al. . Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis. Annals of Hepatology, (2022); 27(2): 1-6.

Tovo C V. V-NC, Leite NC, Panke CL, Port GZ, Fernandes S, et al. Transient hepatic elastography has the best performance in evaluating liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Annals of hepatology, (2019); 18(3): 445–449.

Vuppalanchi R ÜA, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, et al. Effects of Liver Biopsy Sample Length and Number of Readings on Sampling Variability in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, (2009); 7(4): 481–486.

Contreras D G-RA, Clark P, Barquera S, Denova-Gutiérrez E. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis. Annals of Hepatology, (2023); 28(1): 1-10.

Chalasani N YZ, Lavine JE, Charlton M, Cusi K, Rinella M, et al.. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, (2018); 67(1): 328-357.

Tokushige K IK, Ono M, Eguchi Y, Kamada Y, Itoh Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. Hepatology Research, (2021); 51(10): 1013-1025.

HY. K. Recent advances in nonalcoholic fatty liver disease metabolomics. Clinical and molecular hepatology, (2021); 27(4): 553-559.

Mikolasevic I DV, Krznaric-Zrnic I, Krznaric Z, Virovic-Jukic L, Stojsavljevic S, Grgurevic I, Milic S, Vukoja I, Puz P, Aralica M, Hauser G. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. Medicina, (2022); 58(2): 1-14.

Chung J PH, Kim YJ, Yu MH, Park S, Jung SI. Association of Hepatic Steatosis Index with Nonalcoholic Fatty Liver Disease Diagnosed by Non-Enhanced CT in a Screening Population. Diagnostics (Basel), (2021); 11(12).

Martinou E PM, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics, (2022); 12(2): 1-11.




DOI: http://dx.doi.org/10.62940/als.v11i2.2769

Refbacks

  • There are currently no refbacks.